Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 17, 2015, 79 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $428.00 to $8,749,928.65.

Highlighted Stocks Traded by Insiders:

Vectren (VVC) - FREE Research Report

Jones Robert G, who is Director at Vectren, bought 91 shares at $43.33 on March 17, 2015. Following this transaction, the Director owned 2,029 shares meaning that the stake was boosted by 4.7% with the 91-share transaction.

The shares most recently traded at $43.58, up $0.25, or 0.57% since the insider transaction. Historical insider transactions for Vectren go as follows:

  • 4-Week # shares bought: 82
  • 12-Week # shares bought: 82
  • 24-Week # shares bought: 82

The average volume for Vectren has been 504,200 shares per day over the past 30 days. Vectren has a market cap of $3.6 billion and is part of the utilities sector and utilities industry. Shares are down 6.86% year-to-date as of the close of trading on Tuesday.

Vectren Corporation provides energy delivery services to residential, commercial, and industrial and other contract customers. The stock currently has a dividend yield of 3.5%. The company has a P/E ratio of 21.5. Currently, there are 2 analysts who rate Vectren a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VVC - FREE

TheStreet Quant Ratings

rates Vectren as a

buy

. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, notable return on equity, solid stock price performance and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Vectren Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Universal Insurance Holdings (UVE) - FREE Research Report

Pietrangelo Michael, who is Director at Universal Insurance Holdings, sold 10,000 shares at $25.05 on March 17, 2015. Following this transaction, the Director owned 91,248 shares meaning that the stake was reduced by 9.88% with the 10,000-share transaction.

Downes Sean P, who is President and CEO at Universal Insurance Holdings, sold 20,000 shares at $24.78 on March 17, 2015. Following this transaction, the President and CEO owned 1.6 million shares meaning that the stake was reduced by 1.22% with the 20,000-share transaction.

The shares most recently traded at $24.93, up $0.15, or 0.6% since the insider transaction. Historical insider transactions for Universal Insurance Holdings go as follows:

  • 4-Week # shares bought: 1,500
  • 4-Week # shares sold: 45,228
  • 12-Week # shares bought: 1,500
  • 12-Week # shares sold: 112,228
  • 24-Week # shares bought: 1,500
  • 24-Week # shares sold: 284,748

The average volume for Universal Insurance Holdings has been 375,800 shares per day over the past 30 days. Universal Insurance Holdings has a market cap of $894.4 million and is part of the financial sector and insurance industry. Shares are up 23.13% year-to-date as of the close of trading on Tuesday.

Universal Insurance Holdings, Inc., through its subsidiaries, provides various property and casualty insurance products. It primarily underwrites homeowners' insurance products; and offers reinsurance intermediary brokerage services. The stock currently has a dividend yield of 1.66%. The company has a P/E ratio of 12.2. Currently, there are no analysts who rate Universal Insurance Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on UVE - FREE

TheStreet Quant Ratings

rates Universal Insurance Holdings as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full

Universal Insurance Holdings Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Medtronic (MDT) - FREE Research Report

Ishrak Omar, who is Chairman & CEO at Medtronic, sold 20,000 shares at $76.24 on March 17, 2015. Following this transaction, the Chairman & CEO owned 554,396 shares meaning that the stake was reduced by 3.48% with the 20,000-share transaction.

The shares most recently traded at $76.62, up $0.38, or 0.5% since the insider transaction. Historical insider transactions for Medtronic go as follows:

  • 4-Week # shares sold: 12,855
  • 12-Week # shares sold: 12,855
  • 24-Week # shares sold: 43,057

The average volume for Medtronic has been 8.6 million shares per day over the past 30 days. Medtronic has a market cap of $110.7 billion and is part of the health care sector and health services industry. Shares are up 6.26% year-to-date as of the close of trading on Tuesday.

Medtronic plc, a healthcare solutions company, provides medical technologies, services, and solutions worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. The stock currently has a dividend yield of 1.57%. The company has a P/E ratio of 24.9. Currently, there are 15 analysts who rate Medtronic a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDT - FREE

TheStreet Quant Ratings

rates Medtronic as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, solid stock price performance, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

Medtronic Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null